nACfiR upregulation by ciironic exposure to nicotine and ottier nicotinic drugs The Overall Progress Report and Overall Description sections provide the logic and background for the study of receptor upregulation by candidate drugs. Upregulation in 2 pathways related to nicotine addiction Cellular and circuit-level research on nAChRs is governed by the fact that only a handful of papers present believable eEPSCs, sEPSCs, or mEPSCs associated with nAChR activation by ACh in the brain. Investigators believe that most HS nicotinic receptors are on presynaptic terminals, where they control transmitter release (and therefore pose challenges for detailed study) (MacDermott et al., 1999). Many studies also reveal the presence of somatodendritic HS nAChRs (mostly a4B2* and a6*). Little or no evidence shows that these somatodendritic receptors respond to circulating or released ACh. But there is much evidence that these nAChRs do respond to nicotine with both activation and, in some cases, desensitization, primarily because nicotine is not hydrolyzed by acetylcholinesterase.

National Institute of Health (NIH)
National Institute on Drug Abuse (NIDA)
Research Program--Cooperative Agreements (U19)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-C)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
California Institute of Technology
United States
Zip Code
Wang, Yuexiang; Lee, Jang-Won; Oh, Gyeon et al. (2014) Enhanced synthesis and release of dopamine in transgenic mice with gain-of-function *6* nAChRs. J Neurochem 129:315-27
Limapichat, Walrati; Dougherty, Dennis A; Lester, Henry A (2014) Subtype-specific mechanisms for functional interaction between ?6?4* nicotinic acetylcholine receptors and P2X receptors. Mol Pharmacol 86:263-74
Eaton, J Brek; Lucero, Linda M; Stratton, Harrison et al. (2014) The unique *4+/-*4 agonist binding site in (*4)3(*2)2 subtype nicotinic acetylcholine receptors permits differential agonist desensitization pharmacology versus the (*4)2(*2)3 subtype. J Pharmacol Exp Ther 348:46-58
Wageman, Charles R; Marks, Michael J; Grady, Sharon R (2014) Effectiveness of nicotinic agonists as desensitizers at presynaptic *4*2- and *4*5*2-nicotinic acetylcholine receptors. Nicotine Tob Res 16:297-305
Henderson, Brandon J; Srinivasan, Rahul; Nichols, Weston A et al. (2014) Nicotine exploits a COPI-mediated process for chaperone-mediated up-regulation of its receptors. J Gen Physiol 143:51-66
O'Neill, Heidi C; Laverty, Duncan C; Patzlaff, Natalie E et al. (2013) Mice expressing the ADNFLE valine 287 leucine mutation of the ýý2 nicotinic acetylcholine receptor subunit display increased sensitivity to acute nicotine administration and altered presynaptic nicotinic receptor function. Pharmacol Biochem Behav 103:603-21
Marks, Michael J (2013) Genetic matters: thirty years of progress using mouse models in nicotinic research. Biochem Pharmacol 86:1105-13
Ortiz, Nick C; O'Neill, Heidi C; Marks, Michael J et al. (2012) Varenicline blocks ?2*-nAChR-mediated response and activates ?4*-nAChR-mediated responses in mice in vivo. Nicotine Tob Res 14:711-9
Grady, Sharon R; Wageman, Charles R; Patzlaff, Natalie E et al. (2012) Low concentrations of nicotine differentially desensitize nicotinic acetylcholine receptors that include ýý5 or ýý6 subunits and that mediate synaptosomal neurotransmitter release. Neuropharmacology 62:1935-43
Xiao, Cheng; Srinivasan, Rahul; Drenan, Ryan M et al. (2011) Characterizing functional ýý6ýý2 nicotinic acetylcholine receptors in vitro: mutant ýý2 subunits improve membrane expression, and fluorescent proteins reveal responsive cells. Biochem Pharmacol 82:852-61

Showing the most recent 10 out of 20 publications